CI

At a glance

ClinicalIndex Comparison Record
Phase 4Unknown· 100 target
Drug / intervention
Ketorolac +2 moredrug
Likely dose
Ketorolac 30mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04141319
NCT04141319Phase 4Unknown
CompareCT.gov

Effects of Pre-emptive Scalp Infiltration With Ketorolac and Ropivacaine for Postoperative Pain Relief After Elective Supratentorial Craniotomy (PAINLESS)

Beijing Tiantan Hospital·interventional·Posted Oct 28, 2019·Updated Jan 22, 2020

In Brief

A Phase 4 clinical trial evaluating Ketorolac, Ropivacaine, and 1 other intervention for Pain and Supratentorial Brain Tumor. Targeting 100 participants.

Detailed Summary

The PAINLESS study is a single-center, prospective, randomized, open-label, blinded-endpoint (PROBE) controlled clinical study to compare the efficacy and safety of pre-emptive scalp infiltration with ropivacaine plus ketorolac and ropivacaine alone for postoperative pain relief in adults undergoing elective supratentorial craniotomies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain, Supratentorial Brain Tumor
Countries--
Collaborators--

Timeline

Phase 4UnknownOverdue
2020202120222023202420252026
First PostedOct 28, 2019
Enrollment StartDec 1, 2021
Primary CompletionJul 1, 2022
Study CompletionDec 1, 2022
TodayJul 1, 2026
Enrollment to primary: 7 monthsPosted 6.7 years ago

Interventions

Ketorolacdrug

30ml of local infiltration solution containing 60mg ropivacaine

Ropivacainedrug

30ml of local infiltration solution containing 6mg ketorolac

Epinephrinedrug

30ml of local infiltration solution containing 0.1mg epinephrine